<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4980">
  <stage>Registered</stage>
  <submitdate>12/05/2015</submitdate>
  <approvaldate>12/05/2015</approvaldate>
  <nctid>NCT02449681</nctid>
  <trial_identification>
    <studytitle>Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS</studytitle>
    <scientifictitle>A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TH-CR-602</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TH-4000

Experimental: TH-4000 (Tarloxotinib) - 


Treatment: drugs: TH-4000


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with response rate as evaluated by RECIST criteria</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (AEs)</outcome>
      <timepoint>Up to 30 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Type of adverse events (AEs)</outcome>
      <timepoint>Up to 30 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of adverse events (AEs)</outcome>
      <timepoint>Up to 30 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) calculated for all patients achieving an objective response</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum plasma concentration of TH4000 (prodrug) and TH-4000E (TKI effector)</outcome>
      <timepoint>Cycle 1 Day 1 predose and up to 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration versus time curve of TH4000 (prodrug) and TH-4000E (TKI effector)</outcome>
      <timepoint>Cycle 1 Day 1 predose and up to 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QTc Interval</outcome>
      <timepoint>Screening, Cycle 1 Day 1, 8, 15 &amp; 22, Day 1 and study Termination</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Confirmed squamous cell carcinoma of the head and neck (oropharynx, oral cavity,
             hypopharynx, or larynx) or skin

          -  For patients with oropharyngeal cancer, p16 status is known or can be determined

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors version
             1.1 (RECIST 1.1)

          -  Acceptable laboratory results as indicated by protocol

          -  Acceptable cardiac function as indicated by protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Received prior EGFR TKI therapy for recurrent or metastatic SCC (e.g., oral EGFR TKIs
             such as erlotinib, gefitinib, or afatinib)

          -  Family history of long QTc syndrome

          -  Receiving medication that prolongs QT interval ,with a risk of causing Torsades de
             Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the
             medication

          -  Family history of long QTc syndrome

          -  Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy

          -  Radiation therapy within 2 weeks prior to the first dose of study medication

          -  Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose
             of study medication

          -  Concurrent active malignancy requiring systemic treatment

          -  Any other serious uncontrolled medical disorders or psychological conditions that may
             interfere with study conduct including but not limited to: clinically significant
             active infection

          -  Pregnant or breast-feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/01/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Chris O'Brien Lifehouse - Camperdown</hospital>
    <hospital>Peter MacCallum - East Melbourne</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Threshold Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib),
      a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell
      carcinoma of the head and neck or skin.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02449681</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen Liu</name>
      <address>Georgetown University Hospital Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>